In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 4 | 8 | 0 | 1 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 4 | 3 | 4 | 0 | 1 |
| 3M Ago | 0 | 1 | 4 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $499.21, a high estimate of $600.00, and a low estimate of $408.00. This current average has increased by 3.38% from the previous average price target of $482.88.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Vertex Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Yee | Jefferies | Raises | Buy | $550.00 | $500.00 |
| Geoff Meacham | Citigroup | Announces | Buy | $575.00 | - |
| Whitney Ijem | Canaccord Genuity | Raises | Sell | $408.00 | $361.00 |
| Greg Harrison | Scotiabank | Raises | Sector Perform | $486.00 | $480.00 |
| Colin Bristow | UBS | Raises | Buy | $586.00 | $562.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $480.00 | $480.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $451.00 | $437.00 |
| Jessica Fye | JP Morgan | Lowers | Overweight | $503.00 | $510.00 |
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $476.00 | $473.00 |
| Hartaj Singh | Oppenheimer | Lowers | Outperform | $540.00 | $550.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $600.00 | $600.00 |
| Colin Bristow | UBS | Raises | Buy | $562.00 | $477.00 |
| Greg Harrison | Scotiabank | Announces | Sector Perform | $480.00 | - |
| Ying Huang | B of A Securities | Lowers | Buy | $541.00 | $550.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $437.00 | $425.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $480.00 | $480.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $425.00 | $431.00 |
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $474.00 | $462.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $431.00 | $431.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vertex Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Vertex Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
To gain a panoramic view of Vertex Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Vertex Pharmaceuticals analyst ratings.
Discovering Vertex Pharmaceuticals: A Closer Look
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
A Deep Dive into Vertex Pharmaceuticals's Financials
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Vertex Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.61%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 37.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 6.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.93% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
How Are Analyst Ratings Determined?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
